Compare EME & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EME | BIIB |
|---|---|---|
| Founded | 1987 | 1978 |
| Country | United States | United States |
| Employees | 25000 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 34.5B |
| IPO Year | 1994 | 1996 |
| Metric | EME | BIIB |
|---|---|---|
| Price | $607.37 | $250.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 36 |
| Target Price | ★ $875.60 | $268.26 |
| AVG Volume (30 Days) | 485.8K | ★ 1.1M |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | ★ 30.99 | N/A |
| EPS | ★ 24.93 | 2.66 |
| Revenue | ★ $16,986,422,000.00 | $9,890,600,000.00 |
| Revenue This Year | $23.11 | $7.00 |
| Revenue Next Year | $13.99 | $1.82 |
| P/E Ratio | ★ $25.52 | $92.96 |
| Revenue Growth | ★ 16.62 | 2.22 |
| 52 Week Low | $579.48 | $160.36 |
| 52 Week High | $951.96 | $261.00 |
| Indicator | EME | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 54.94 |
| Support Level | $579.48 | $240.00 |
| Resistance Level | $858.99 | $259.89 |
| Average True Range (ATR) | 26.58 | 7.20 |
| MACD | 0.13 | -1.24 |
| Stochastic Oscillator | 19.48 | 50.24 |
Emcor designs, installs, and maintains a host of electrical and mechanical systems, including power, communications, HVAC, and plumbing, for a variety of customers, including data centers, semiconductor fabs, healthcare, and water treatment. It operates through more than 100 subsidiaries and actively pursues bolt-on acquisitions to expand into additional geographies in the USA.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).